Bump in the road for AZ and Amgen’s severe asthma candidate

AstraZeneca and Amgen had been hoping the broad-reaching mechanism of tezepelumab would prove useful across the full spectrum of severe asthma patients. Those prospects dimmed a little on Tuesday when the company reported a Phase III miss in a patient subset dependent on oral steroids, but there’s still plenty of room for tezepelumab to expand the market.

And with positive Phase III data in hand from a much larger trial, the partners may not need the new data for regulatory purposes...